US-based protein stabilisation technology developer Stablix Therapeutics launched yesterday with $63m in series A funding from investors including life science real estate investment trust Alexandria Real Estate Equities.
The round was led by venture capital firm Versant Ventures and included New Enterprise Associates, Cormorant Capital and Euclidean Capital while Alexandria Real Estate Equities took part through its Alexandria Venture Investments unit.
Stablix has developed targeted protein stabilisation technology that has applications in the treatment of rare diseases, cancer and immunological disorders. It is recruiting researchers for a laboratory facility in New York City and will use the capital to build out its platform and advance several candidates toward clinical trials.
Carlo Rizzuto, partner at Versant and acting chief executive of Stablix, said: “Stablix possesses a first-in-category platform that can restore protein stability and function in a target-selective manner.
“We are very pleased to launch this company to address this important therapeutic white space for numerous devastating diseases.”
The original version of this article appeared on our sister site, Global University Venturing.
